Health products distributor Bod Australia Ltd has been granted an import license for medicinal cannabis products
The license allows Bod to store and supply medicinal cannabis.
The company said it will now seek permission from the Office of Drug Control, or ODC, to import a range of cannabis products from overseas producers and raw materials from its exclusive partner, Linnea SA. Linnea is a Switzerland-based maker of medicinal cannabis extracts, botanical and pharmaceutical ingredients for use in the pharmaceutical, nutraceutical and cosmetic sectors.
Products containing the plant will be available to authorized prescribers and will be used for the company's clinical trial programs once Bod secures an approval from the ODC.
The move marks a key step for Bod in establishing medical cannabis operations in Australia and improving revenues from the sale of therapeutic goods and extracts. The company said phase 1 of its clinical trial, which aims to test the safety, tolerability and pharmacokinetics of the Linnea phytocomplex cannabis extract, is expected to start in 2018.
